Geldanamycin inhibits Jumonji histone lysine demethylase KDM4 and targets chimeric transcription factor PAX3-FOXO1
A. Abu-Zaid, S. Singh, W. LIN, J. Low, A. Abdolvahabi, B. Bailey Cooke, J. Bowling, S. Vaithiyalingam, J. Fang, D. Currier, M.-K. Yun, A. AlTahan, D. Fernando, J. Maier, H. Tillman, , J. YANG
This study identifies geldanamycin and its analog 17-DMAG as dual KDM/Hsp90 inhibitors effective against PAX3-FOXO1-driven rhabdomyosarcoma.
bioRxiv · Dec 11, 2019 · PreprintCancer Biology